XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
MENLO PARK, Calif., October 16, 2007 /PRNewswire-FirstCall/ -- XTENT, Inc. today announced that 2-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company's investigational Custom NX(R) drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.
In addition, the company will conduct a number of activities during the meeting including an analyst webcast and teleconference to review the CUSTOM I and CUSTOM II clinical data, an evening drug-eluting stent symposium, and an exhibition at booth 6097 on Level 2 of the Washington Convention Center.
Schedule of Events Sunday, October 21 Event: The Drug-Eluting Stent Summit: The XTENT CUSTOM Biolimus-Eluting Modular Stent Program (Focus on Multivessel and Diffuse Disease) Pieter Stella, M.D., Director of Cardiology, University Medical Center, Utrecht, Netherlands, will present a historical overview and current perspective on the treatment of multivessel coronary disease and the treatment of long lesions. An overview of the Custom NX(R) DES System with respect to the treatment of multivessel and diffuse disease will be discussed, along with the one-year follow-up results of the CUSTOM II Trial. Time/Location: 3:16-3:26 p.m. EDT; Ballroom C, 3rd Floor, Washington Convention Center Event: Evening Symposium -- Delivering Safety to Today's Patients Professor Eberhard Grube, M.D., Chief of Cardiology at the HELIOS Heart Center in Siebgurg, Germany and principal investigator of the CUSTOM I and II clinical trials, will review the results to date from Biolimus A9(R) DES clinical trials and registries. Professor Grube will present two-year results from the CUSTOM I clinical trial and one-year results from the CUSTOM II clinical trial. Bernard de Bruyne, M.D. Ph.D, Cardiovascular Center, OLV Hospital in Aalst, Belgium, will provide an overview of the Custom NX technology in a presentation titled "XTENT Custom NX DES Systems: A Novel Approach to the Percutaneous Treatment of Coronary Artery Disease (CAD)." Time/Location: 8:00-10:00 p.m. EDT; Renaissance Washington, D.C. Hotel, Grand Ballroom, 999 Ninth Street NW Monday, October 22 Event: Analyst Webcast and Teleconference on CUSTOM I and CUSTOM II Data XTENT will host a webcast and teleconference call to review the CUSTOM I and CUSTOM II data presented on Sunday. The teleconference and slide presentation can be accessed via the investor relations section of the company's website at http://investor.xtentinc.com/events.cfm or by calling 888-663-2258 (from the U.S.), 913-312-1277 (international). Please dial in or access the website five to ten minutes prior to the beginning of the call. The webcast will be archived on the website for a minimum of three months, and can be accessed at the investor relations portion of the company's website at http://investor.xtentinc.com Time/Location: 7:00 a.m. EDT
XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT Custom NX DES Systems have not been approved for sale by any regulatory authority.
Information about XTENT is available at our website at http://www.xtentinc.com.
CONTACT: investors, Tim Kahlenberg, Chief Financial Officer of XTENT,Inc., +1-650-475-9400, ; or media relations, AimeeCorso, +1-310-780-2661, , for XTENT, Inc. firstname.lastname@example.org email@example.com
Web site: http://www.xtentinc.com/
Ticker Symbol: (NASDAQ-NMS:XTNT)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: October 2007